Nasus Pharma (NSRX) Cash & Equivalents (2024 - 2025)
Nasus Pharma (NSRX) reported Cash & Equivalents of $1.2 million for Q4 2025, up 335.56% on a YoY basis from $284000.0 in Q4 2024, and up 433.19% quarter-over-quarter from $232000.0 in Q2 2025.
Nasus Pharma (NSRX) Cash & Equivalents (2024 - 2025) Analysis & Trends
Nasus Pharma has reported Cash & Equivalents for 2 years, with the latest figure at $1.2 million in Q4 2025.
- For the quarter ending Q4 2025, Cash & Equivalents rose 335.56% year-over-year to $1.2 million; the trailing twelve-month figure through Dec 2025 stood at $1.2 million (up 335.56% YoY), and the FY2025 full-year result was $1.2 million, up 335.56% from the prior year.
- Cash & Equivalents for Q4 2025 stood at $1.2 million, up from $232000.0 in the prior quarter.
- The five-year high for Cash & Equivalents was $1.2 million in Q4 2025, with the low at $232000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | 4.64 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 5.28 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 21.69 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 9.39 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 5.33 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 12.04 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 7.63 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 1.70 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 9.57 Bn |
| 10 | Nasus Pharma | 23.47 Mn | 19.18 Mn | - | 1.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.24 Mn |
| Jun 30, 2025 | 232,000.00 |
| Dec 31, 2024 | 284,000.00 |